Print this page
Radiation
-
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Protocol: 032506Applicable Disease Sites: Lung
-
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer.
Protocol: 032507Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
Protocol: 032506Applicable Disease Sites: Lung
-
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination with Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III Non-Small Cell Lung Cancer.
Protocol: 032507Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
Protocol: 042208Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
Protocol: 042208Principal Investigator:
- Coral Omene
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
Protocol: 042405Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy.
Protocol: 042405Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast